期刊文献+

Sirolimus-eluting stents for treatment of drug-eluting versus bare-metal stents restenosis: 42-month clinical outcomes from a Chinese single center 被引量:2

Sirolimus-eluting stents for treatment of drug-eluting versus bare-metal stents restenosis: 42-month clinical outcomes from a Chinese single center
原文传递
导出
摘要 Background Restenosis of bare-metal stents (BMS) and drug-eluting stents (DES) has been increasingly treated with sirolimus-eluting stents (SES), but the long-term outcomes are unknown. Methods In our study, 388 consecutive patients (144 DES restenosis and 244 BMS restenosis) with 400 lesions (147 DES restenosis and 253 BMS restenosis) treated with SES were included. The rates of target lesion revascularization (TLR) and major adverse cardiac events (MACE) at 42 months were analyzed. Results At the mean follow-up of 42 months, the rates of death (3.5% vs. 3.3%, P=1.000) and myocardial infarction (2.8% vs. 1.2%, P=0.431) in the DES group and BMS group were comparable. Compared with the BMS group, ischemia-driven TLR occurred with a higher frequency in the DES group (18.8% vs.10.7%, P=0.024). This translated into an increased rate of MACE in the DES group (22.2% vs. 14.0%, P=0.034). Stent thrombosis occurred with a similar frequency in both groups (2.8% vs. 1.6%, P=0.475). Multivariate analysis showed that DES restenosis (OR=1.907, 95% Cl 1.108-3.285, P=0.020) and smoking (OR=2.069; 95% Cl 1.188-3.605; P=0.010) were independent predictors of MACE. Background Restenosis of bare-metal stents (BMS) and drug-eluting stents (DES) has been increasingly treated with sirolimus-eluting stents (SES), but the long-term outcomes are unknown. Methods In our study, 388 consecutive patients (144 DES restenosis and 244 BMS restenosis) with 400 lesions (147 DES restenosis and 253 BMS restenosis) treated with SES were included. The rates of target lesion revascularization (TLR) and major adverse cardiac events (MACE) at 42 months were analyzed. Results At the mean follow-up of 42 months, the rates of death (3.5% vs. 3.3%, P=1.000) and myocardial infarction (2.8% vs. 1.2%, P=0.431) in the DES group and BMS group were comparable. Compared with the BMS group, ischemia-driven TLR occurred with a higher frequency in the DES group (18.8% vs.10.7%, P=0.024). This translated into an increased rate of MACE in the DES group (22.2% vs. 14.0%, P=0.034). Stent thrombosis occurred with a similar frequency in both groups (2.8% vs. 1.6%, P=0.475). Multivariate analysis showed that DES restenosis (OR=1.907, 95% Cl 1.108-3.285, P=0.020) and smoking (OR=2.069; 95% Cl 1.188-3.605; P=0.010) were independent predictors of MACE.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第19期3398-3403,共6页 中华医学杂志(英文版)
关键词 RESTENOSIS percutaneous coronary intervention drug-eluting stents restenosis percutaneous coronary intervention drug-eluting stents
  • 相关文献

参考文献24

  • 1Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR,O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
  • 2Stone GW, Ellis SG; Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
  • 3Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Sch6mig A, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948.
  • 4Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. ESIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
  • 5Schampaert E, Cohen EA, Schliiter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). JAm Coll Cardiol 2004; 43: 1110-1115.
  • 6Lloyd-Jones D, Adams R, Carnethon M, De Simone Ferguson TB, Flegal K, et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119: 480-486.
  • 7Tagliareni F, La Manna A, Saia F, Marzocchi A, Tamburino C. Long-term clinical follow-up of drug-eluting stent restenosis treatment: retrospective analysis from two high volume catheterization laboratories. EuroIntervention 2010; 5: 703-708.
  • 8Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura Y, Kuroda N, et al. Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: retrospective analysis of 4 Japanese hospitals. Circ J 2009; 73: 867-871.
  • 9Dibra A, Kastrati A, Alfonso F, Seyfarth M, P6rez-Vizcayno MJ, Mehilli J, et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: Meta-analysis of randomized trials. J Am Coil Cardiol 2007; 49: 616-623.
  • 10Liistro F, Fineschi M, Angioli P, Sinicropi G, Faisini G, Gori T, et al. Effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: The TRUE (Tuscany registry of sirolimus for unselected in-stent restenosis) registry. J Am Coll Cardiol 2006; 48: 270-275.

同被引文献3

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部